Head-to-head evidence
BEBT-109 vs BPI-361175
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BEBT-109
Developed by BeBetter Med
NCT06001671 · Phase 1 · completed
This was a small, single-arm, dose-escalation study with no control group and effectively no blinding of participants or investigators; it was designed to find a tolerable dose, not to test whether the drug worked, and results have not yet been reported.
Next expected readout: June 2027 · NCT06514027 (registry estimate)
BPI-361175
Developed by Betta Pharmaceuticals Co.
NCT05329298 · Phase 1/2 · status unknown
This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BEBT-109's landscape · BPI-361175's landscape